Compare EUDA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EUDA | COCH |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.8M | 49.9M |
| IPO Year | 2021 | 2021 |
| Metric | EUDA | COCH |
|---|---|---|
| Price | $14.80 | $7.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.67 |
| AVG Volume (30 Days) | 32.9K | ★ 104.4K |
| Earning Date | 12-19-2023 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | $299.28 | N/A |
| Revenue Next Year | N/A | $17.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $0.33 | $0.36 |
| 52 Week High | $25.70 | $6.61 |
| Indicator | EUDA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 97.91 |
| Support Level | $14.21 | $0.61 |
| Resistance Level | $15.36 | N/A |
| Average True Range (ATR) | 1.49 | 0.25 |
| MACD | -0.32 | 0.60 |
| Stochastic Oscillator | 28.95 | 95.24 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.